>
Bionik Laboratories logo

BNKL - Bionik Laboratories Share Price

$2.86 0.0  0.0%

Last Trade - 14/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £10.4m
Enterprise Value £12.9m
Revenue £1.20m
Position in Universe 6288th / 6854
Bullish
Bearish
Unlock BNKL Revenue
Momentum
Relative Strength (%)
1m +33.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -36.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.57 0.99 3.25 2.15
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, BionikLaboratories Corp revenues decreased 41% to $731K. Net lossincreased 49% to $12.6M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsForeign exchange decrease from $111K (income) to $30K(expense), Interest expense increase from $0K to $79K(expense), Other income decrease of 22% to $84K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BNKL Revenue Unlock BNKL Revenue

Net Income

BNKL Net Income Unlock BNKL Revenue

Normalised EPS

BNKL Normalised EPS Unlock BNKL Revenue

PE Ratio Range

BNKL PE Ratio Range Unlock BNKL Revenue

Dividend Yield Range

BNKL Dividend Yield Range Unlock BNKL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BNKL EPS Forecasts Unlock BNKL Revenue
Profile Summary

Bionik Laboratories Corp. (Bionik), formerly Drywave Technologies, Inc., is a medical device and robotics company. The Company is focused on providing rehabilitation solutions and developing transformational technologies and solutions to individuals with neurological disorders, specializing in the designing, developing and commercializing of physical rehabilitation technologies, prosthetics and assisted robotic products. It has over three products on the market and approximately three products in various stages of development. The InMotion Systems include the InMotion ARM, InMotion HAND, InMotion Wrist and InMotion ANKLE are designed to provide patent-adaptive therapy in a manner that has been clinically verified to manage neuro-recovery. The Company is also engaged in developing a lower-body exoskeleton, ARKE, which designs to allow paraplegics, as well as other wheelchair users the ability to rehabilitate through walking.

Directors
Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated June 25, 2013
Public Since June 12, 2012
No. of Shareholders: 313
No. of Employees: 18
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 5,004,984
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
BNKL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BNKL
Upcoming Events for BNKL
Frequently Asked Questions for Bionik Laboratories
What is the Bionik Laboratories share price?

As of 14/04/21, shares in Bionik Laboratories are trading at $2.86, giving the company a market capitalisation of £10.4m. This share price information is delayed by 15 minutes.

How has the Bionik Laboratories share price performed this year?

Shares in Bionik Laboratories are currently trading at $2.86 and the price has moved by 63.43% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bionik Laboratories price has moved by 8% over the past year.

What are the analyst and broker recommendations for Bionik Laboratories?

Of the analysts with advisory recommendations for Bionik Laboratories, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Bionik Laboratories is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Bionik Laboratories next release its financial results?

Bionik Laboratories is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bionik Laboratories dividend yield?

Bionik Laboratories does not currently pay a dividend.

Does Bionik Laboratories pay a dividend?

Bionik Laboratories does not currently pay a dividend.

When does Bionik Laboratories next pay dividends?

Bionik Laboratories does not currently pay a dividend.

How do I buy Bionik Laboratories shares?

To buy shares in Bionik Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bionik Laboratories?

Shares in Bionik Laboratories are currently trading at $2.86, giving the company a market capitalisation of £10.4m.

Where are Bionik Laboratories shares listed? Where are Bionik Laboratories shares listed?

Here are the trading details for Bionik Laboratories:

Country of listing: United States
Exchange: PNK
Ticker Symbol: BNKL
What kind of share is Bionik Laboratories?

Based on an overall assessment of its quality, value and momentum, Bionik Laboratories is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bionik Laboratories share price forecast 2021?

We were not able to load any forecast data for Bionik Laboratories.

How can I tell whether the Bionik Laboratories share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionik Laboratories. Over the past six months, the relative strength of its shares against the market has been 99.68%. At the current price of $2.86, shares in Bionik Laboratories are trading at 31.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bionik Laboratories PE Ratio?

We were not able to find PE ratio data for Bionik Laboratories.

Who are the key directors of Bionik Laboratories?

Bionik Laboratories's management team is headed by:

Michal Prywata - CTO
Leslie Markow - CFO
Eric Dusseux - CEO
Remi Gaston-Dreyfus - IND
Andre-Jacques Auberton-Herve - CHM
Peter Malone - IND
Audrey Thevenon - IND
Charles Matine - IND
Joseph Martin - IND
Loren Wass - OTH
Rich Russo - CFO
Who are the major shareholders of Bionik Laboratories?

Here are the top five shareholders of Bionik Laboratories based on the size of their shareholding:

Gaston-Dreyfus (Remi) Individual Investor
Percentage owned: 23.99% (1.20m shares)
Dassault (Olivier) Individual Investor
Percentage owned: 13.87% (694k shares)
Celeste Management SA Corporation
Percentage owned: 13.12% (657k shares)
SFP Capital LLC Corporation
Percentage owned: 9.55% (478k shares)
Auberton-Herve (Andre-Jacques Ph.D.) Individual Investor
Percentage owned: 6.39% (320k shares)
Similar to BNKL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.